 NEW YORK, Aug. 04, 2020 GLOBE NEWSWIRE -- Daxor Corporation NYSE MKT: DXR, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement CRADA with The Uniformed Services University of the Health Sciences USU, an institution of higher learning within the United States Department of Defense DoD, and The Henry M. Jackson Foundation for the Advancement of Military Medicine HJF on behalf of USUs Battlefield Shock and Organ Support Research Program BSOS. The partnership includes researching the effectiveness of Daxors BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. Diagnostics currently used to guide battlefield resuscitation and transfusions, such as heart rate, cardiac output, stroke volume, and blood pressure, often misdiagnose the severity of volume derangement, said Michael Feldschuh, CEO and President of Daxor. Daxors BVA-100 Blood Volume Analysis BVA technology can greatly improve the existing standard of care by ensuring treatment decisions based on precise measurement of blood volume for better trauma survival outcomes. Extensive peer-reviewed medical literature has validated Daxors BVAs enhancement of interventions through reliable and accurate blood volume measurement. Most relevant to military medicine is a prospective randomized controlled trial which demonstrated that, compared to standard care, actionable BVA-100 information changed surgical intensive care unit SICU fluid and red blood cell interventions by 44 of cases while reducing patient mortality by 66. Additionally, it cut patients length of stay and days on a ventilator. The collaboration will encompass multiple projects with the ultimate objective of saving the lives of American soldiers and translating the results to civilian care. Target indications include hemorrhage, burn, trauma, sepsis and acute respiratory distress syndrome. Collaborating with USU and HJF is an important milestone as we have been working on new technology and filed patent applications to extend the capabilities of our current FDA-cleared diagnostic system, the BVA-100, for both civilian and military use, said Jonathan Feldschuh, Chief Scientific Officer at Daxor. The results of this work will also support work on the next generation BVA device currently in development under a separate contract with the Department of Defense.About Daxor CorporationDaxor Corporation NYSE: DXR is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100 Blood Volume Analyzer, the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.About HJFThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. HJF is a global nonprofit organization with the mission to advance military medicine. HJFs scientific, administrative and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. With more than 35 years of experience, HJF serves as a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit hjf.org. Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 